-
1 Comment
Hepion Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Hepion Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 98.9% to $-20K since the same quarter in the previous year.
Finally, its free cash flow fell by 88.6% to $-5M since the same quarter in the previous year.
Based on the above factors, Hepion Pharmaceuticals, Inc gets an overall score of 2/5.
Industry | Biotechnology |
---|---|
Sector | Healthcare |
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US4268971045 |
PE Ratio | None |
---|---|
Market Cap | 4M |
Target Price | 30 |
Beta | 1.9 |
Dividend Yield | None |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HEPA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025